These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1931709)

  • 21. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.
    Kaplan EH; Rosen ST; Norris DB; Roenigk HH; Saks SR; Bunn PA
    J Natl Cancer Inst; 1990 Feb; 82(3):208-12. PubMed ID: 2104937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas.
    Bunn PA; Ihde DC; Foon KA
    Int J Cancer Suppl; 1987; 1():9-13. PubMed ID: 3305390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
    Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
    Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
    Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
    Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memorials and mandates for cutaneous lymphomas.
    Heald PW
    Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
    [No Abstract]   [Full Text] [Related]  

  • 27. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
    Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
    Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.
    Bunn PA; Foon KA; Ihde DC; Longo DL; Eddy J; Winkler CF; Veach SR; Zeffren J; Sherwin S; Oldham R
    Ann Intern Med; 1984 Oct; 101(4):484-7. PubMed ID: 6332565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
    Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
    Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
    Altomare GF; Capella GL; Pigatto PD; Finzi AF
    Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
    Safai B
    Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
    J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon-alpha and PUVA therapy for mycosis fungoides].
    Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
    Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
    Spaccarelli N; Rook AH
    Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
    Golling P; Cozzio A; Dummer R; French L; Kempf W
    Leuk Lymphoma; 2008 Jun; 49(6):1094-103. PubMed ID: 18569636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
    Thomas BR; Whittaker S
    Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
    Rupoli S; Barulli S; Guiducci B; Offidani M; Mozzicafreddo G; Simonacci M; Filosa G; Giacchetti A; Ricotti G; Brandozzi G; Cataldi I; Serresi S; Ceschini R; Bugatti L; Offidani A; Giangiacomi M; Brancorsini D; Leoni P
    Haematologica; 1999 Sep; 84(9):809-13. PubMed ID: 10477454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.